May 9 |
Regulus Therapeutics GAAP EPS of -$0.29
|
May 9 |
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
|
May 7 |
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
|
May 6 |
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Apr 30 |
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
|
Apr 10 |
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
|
Apr 9 |
Regulus files to sell 62.5M shares of common stock for holders
|
Mar 23 |
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
|
Mar 21 |
Regulus Therapeutics GAAP EPS of -$0.40 in-line
|
Mar 21 |
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
|